首页 / 院系成果 / 成果详情页

A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer 期刊论文

编号：

33b5f81e-7d60-47e1-b8dc-4a48fa381e89
作者：

Lu, Shun(陆舜)#*^[1]Li, Lu^[2];Luo, Yi^[3];Zhang, Li^[4];Wu, Gang^[5];Chen, Zhiwei^[1];Huang, Cheng^[6];Guo, Shuliang^[7];Zhang, Yiping^[8];Song, Xiangqun^[9];Yu, Yongfeng^[1];Zhou, Caicun^[10];Li, Wei(李薇)^[11]Liao, Meilin^[1];Li, Baolan^[12];Xu, Liyan^[12];Chen, Ping^[13];Hu, Chunhong^[13];Hu, Chengping^[14];
语种：

English
期刊：

JOURNAL OF THORACIC ONCOLOGY ISSN：1556-0864 2015 年 10 卷 1 期 (206 - 211) ; JAN
收录：
关键词：

Etoposide Carboplatin Rh-endostatin Extensive-stage small-cell lung cancer Survival
摘要：

Background: Based on promising efficacy in a single-arm study, a randomized phase II trial was designed to compare the efficacy and safety of adding rh-endostatin (Endostar) to first-line standard etoposide and carboplatin (EC) chemotherapy for treatment of extensive-stage small-cell lung cancer. Methods: One hundred forty Chinese patients with pathologically confirmed, extensive-stage small-cell lung cancer were randomly assigned to EC alone or rh-endostatin + EC for 4-6 cycles, followed by single-agent rh-endostatin until progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival, Objective response rate (ORR), and quality of life. Results: Median PFS was 6.4 months with rh-endostatin + EC (n = 69) and 5.9 months with EC (n = 69) (hazard ratio 0.8 [95% confidence interval 0.6-1.1]). PFS was significantly higher with rh-endostatin + EC than with EC (hazard ratio 0.4 [0.2-0.9; p = 0.020]) in female. Median overall survival was similar in both groups (12.1 versus 12.4 months, respectively [p = 0.82]). ORR was higher in the rh-endostatin + EC group (75.4%) than in the EC group (66.7%) (p = 0.348). The efficacy of rh-endostatin + EC relative to that of EC was reflected by greater improvements in patient-assessed quality of life scores after 4 and 6 weeks of treatment. There was no difference between each regimen in the incidence of nonhematological or Grade III-IV hematological toxicities. Conclusions: Addition of rh-endostatin to EC for the treatment of extensive-stage small-cell lung cancer had an acceptable toxicity profile, but did not improve overall survival, PFS, and ORR.
推荐引用方式
GB/T 7714：

Lu Shun,Li Lu,Luo Yi, et al. A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer [J].JOURNAL OF THORACIC ONCOLOGY,2015,10(1):206-211.
APA：

Lu Shun,Li Lu,Luo Yi,Zhang Li,&Hu Chengping.(2015).A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer .JOURNAL OF THORACIC ONCOLOGY,10(1):206-211.
MLA：

Lu Shun, et al. "A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer" .JOURNAL OF THORACIC ONCOLOGY 10,1(2015):206-211.
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：61  下载次数：0

分享到：

浏览次数：61

下载次数：0

打印次数：0